XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Summary of Significant Accounting Policies and Recent Accounting Pronouncements      
Service revenue - related party $ 1,926 $ 697 $ 697
Cost of service revenue - related party 1,378    
General and administrative 6,348   8,864
Botaretigene Sparoparvovec     3,957
AAV-hAQP1 4,852   1,663
AAV-CNGB3 / AAV-CNGA3     (1,179)
AAV-GAD 1,459   2,170
Other ocular diseases 1,445   293
Manufacturing 17,359   18,360
Gene Regulation 2,286   2,499
Neurodegenerative diseases 426   391
Preclinical ocular diseases 625   327
Other research and development (1) (624)   541
Johnson & Johnson Innovative Medicine reimbursement     (652)
Share-based compensation 4,887 6,960 6,960
Depreciation and amortization 3,081 3,275 3,275
Total operating expenses 43,522 47,469 47,469
Other segment items (2) 1,615   26,330
Segment net loss (39,981)   (20,442)
Net Income (Loss) $ (39,981) $ (20,442) $ (20,442)